John L Brooks Iii

T1D Exchange is a nonprofit organization that drives meaningful research and innovation in the treatment and prevention of type 1 diabetes (T1D). Through quality improvement and collaboration, we harness data and insights to advance T1D care, identify gaps in data and unmet needs in diabetes care, refine best practices and ultimately improve the care and quality of life of those living with T1D.

Based on a proprietary technology platform, Atentiv develops and markets a new generation of personalized digital learning tools that reverse inattention and impulsivity to significantly improve academic performance and home behavior in children. Atentiv is deeply committed to delivering the promise of new skills for millions of children around the world, so that they can achieve success in school, at home and in life. By working as a team, in partnership with educators and clinicians, we seek to drive transformative change in education and many other areas of unmet educational and clinical need.

We’re uplifting people with #diabetes, breaking down barriers to affordable care, funding lifesaving research, and doing everything we can to end diabetes. Stand with us as #WeFightDiabetes.

Hygieia’s d-Nav® Insulin Management System includes an AI-powered application and helps people with Type 2 diabetes use insulin in a safe and effective way. It works by guiding users to adjust their insulin doses – based on changing blood glucose patterns -- every few days rather than three or four times annually. Studies show that some 90 percent of people using our d-Nav® service achieve lower A1c within three months. Patients tell us they feel better; experience fewer complications; spend less time at their physician’s office; and can lower their disease management costs. The d-Nav® insulin management system was developed by two University of Michigan researchers and has been peer-reviewed with studies published in leading medical journals. Hygieia is headquartered in Livonia, Michigan.

HemoShear Therapeutics is a biotechnology company focused on discovering novel biological targets and developing drugs to treat children’s rare metabolic disorders. Our goal is to discover drugs that save the lives of children who are born with metabolic defects and are unable to sustain basic biochemical processes necessary for life. Our proprietary technology allows us to recapitulate diseases using tissue from livers of children born with genetic defects, interrogate the disrupted biochemical processes, explore drug intervention strategies, and select drug candidates that we believe have high probabilities of clinical success. HemoShear is markedly different from other biotechnology companies because of our proprietary human disease models and our ability to recreate and interpret complex human biology. We believe that no other company can match our ability to understand human hepatic, tumor, or vascular disease biology and translate those findings into discovery of safe and effective drug treatments. We are passionate about understanding disease biology and driven to discover drug treatments that improve health outcomes and save lives. For more information, see www.hemoshear.com.

Uptake Medical® developed innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor®, was the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. Uptake Medical was acquired in July 2016 by Uptake Medical Technology Inc, a subsidiary of Broncus Holding Corp.

PolyPhotonix is a biophotonic research and development company that designs, develops and manufactures non-invasive photonic based medical devices. Established in 2009 in the North East of England, the company is focused on light therapy treatments for macular eye disease and has successfully brought its first medical device through clinical trials to market. The Noctura 400 Sleep Mask is a transformational treatment for Diabetic Retinopathy and Diabetic Macular Oedema, which are serious complications of diabetes and are the principal causes of blindness among people of working age in the UK. For more details visit our product website www.noctura.com. Contact us on: +44 (0) 1740 625 555 Email: enquiries@polyphotonix.com Website: www.polyphotonix.com

T1D Exchange is a nonprofit organization that drives meaningful research and innovation in the treatment and prevention of type 1 diabetes (T1D). Through quality improvement and collaboration, we harness data and insights to advance T1D care, identify gaps in data and unmet needs in diabetes care, refine best practices and ultimately improve the care and quality of life of those living with T1D.

Based on a proprietary technology platform, Atentiv develops and markets a new generation of personalized digital learning tools that reverse inattention and impulsivity to significantly improve academic performance and home behavior in children. Atentiv is deeply committed to delivering the promise of new skills for millions of children around the world, so that they can achieve success in school, at home and in life. By working as a team, in partnership with educators and clinicians, we seek to drive transformative change in education and many other areas of unmet educational and clinical need.

Alira Health is a global healthcare firm whose mission is to humanize healthcare and life sciences in partnership with patients. We provide consulting and clinical services enabled by technology and real-world evidence. From development to medical care, we complement the expertise of our pharma, biotech, and medtech clients with a full spectrum of services across their entire solutions lifecycle.

We’re uplifting people with #diabetes, breaking down barriers to affordable care, funding lifesaving research, and doing everything we can to end diabetes. Stand with us as #WeFightDiabetes.